N
NextCell Pharma AB
STO:NXTCL
NextCell Pharma AB
STO:NXTCL
Price:
1.284
SEK
0.31%
Market Cap:
kr143m
Balance Sheet
Balance Sheet Decomposition
NextCell Pharma AB
NextCell Pharma AB
Balance Sheet Decomposition is not available for
NextCell Pharma AB
NextCell Pharma AB
Balance Sheet
NextCell Pharma AB
NextCell Pharma AB
Currency: SEK
| Aug-2015 | Aug-2016 | Aug-2017 | Aug-2018 | Aug-2019 | Aug-2020 | Aug-2021 | Aug-2022 | Aug-2023 | Aug-2024 | Aug-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
9
|
6
|
17
|
3
|
20
|
22
|
139
|
97
|
50
|
47
|
39
|
|
| Cash |
9
|
6
|
17
|
3
|
20
|
22
|
139
|
97
|
50
|
47
|
39
|
|
| Total Receivables |
0
|
0
|
1
|
0
|
1
|
1
|
2
|
3
|
4
|
3
|
5
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
2
|
3
|
|
| Other Receivables |
0
|
0
|
1
|
0
|
1
|
0
|
0
|
1
|
1
|
1
|
2
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
|
| Other Current Assets |
0
|
0
|
1
|
2
|
2
|
3
|
6
|
6
|
13
|
10
|
10
|
|
| Total Current Assets |
9
|
6
|
18
|
5
|
23
|
26
|
146
|
107
|
67
|
61
|
54
|
|
| PP&E Net |
3
|
3
|
3
|
2
|
2
|
3
|
3
|
10
|
14
|
13
|
14
|
|
| Note Receivable |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
5
|
7
|
7
|
7
|
7
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
12
N/A
|
9
-23%
|
22
+128%
|
9
-61%
|
27
+214%
|
30
+11%
|
156
+423%
|
125
-20%
|
89
-29%
|
81
-8%
|
77
-6%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
1
|
1
|
1
|
1
|
1
|
0
|
1
|
2
|
1
|
6
|
3
|
|
| Accrued Liabilities |
0
|
1
|
1
|
2
|
1
|
2
|
2
|
4
|
8
|
3
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
1
|
1
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
|
| Total Current Liabilities |
2
|
2
|
2
|
3
|
3
|
2
|
4
|
7
|
10
|
10
|
5
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
3
|
4
|
5
|
|
| Total Liabilities |
3
N/A
|
3
+4%
|
3
-5%
|
3
+36%
|
4
+8%
|
4
-5%
|
6
+56%
|
9
+65%
|
13
+44%
|
14
+4%
|
10
-24%
|
|
| Equity | ||||||||||||
| Common Stock |
0
|
1
|
2
|
2
|
4
|
5
|
7
|
7
|
7
|
15
|
23
|
|
| Retained Earnings |
10
|
6
|
17
|
3
|
19
|
21
|
143
|
108
|
69
|
53
|
44
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
10
N/A
|
7
-31%
|
19
+182%
|
5
-74%
|
23
+355%
|
26
+14%
|
150
+472%
|
116
-23%
|
76
-34%
|
68
-11%
|
66
-2%
|
|
| Total Liabilities & Equity |
12
N/A
|
9
-23%
|
22
+128%
|
9
-61%
|
27
+214%
|
30
+11%
|
156
+423%
|
125
-20%
|
89
-29%
|
81
-8%
|
77
-6%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
0
|
12
|
10
|
10
|
23
|
26
|
44
|
44
|
44
|
73
|
111
|
|
Switch to:
Switch to:
See Also
Discover More
